CalciMedica (NASDAQ:CALC) Raised to “Moderate Buy” at Singular Research

Singular Research upgraded shares of CalciMedica (NASDAQ:CALC) to a moderate buy rating in a report issued on Friday morning, Zacks.com reports.

Other analysts have also recently issued reports about the stock. HC Wainwright reiterated a buy rating and issued a $20.00 target price on shares of CalciMedica in a research note on Thursday, June 27th. Oppenheimer reiterated an outperform rating and set a $14.00 price objective on shares of CalciMedica in a research note on Monday, April 1st.

CalciMedica Price Performance

CalciMedica stock opened at $4.25 on Friday. The business has a fifty day moving average price of $5.26 and a 200-day moving average price of $4.63. CalciMedica has a 1-year low of $1.75 and a 1-year high of $8.38. The stock has a market capitalization of $45.69 million, a price-to-earnings ratio of -1.98 and a beta of 1.28.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings results on Monday, May 13th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.07. On average, equities research analysts anticipate that CalciMedica will post -2.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other CalciMedica news, Director Robert N. Wilson acquired 8,443 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were acquired at an average cost of $3.23 per share, with a total value of $27,270.89. Following the acquisition, the director now directly owns 258,918 shares of the company’s stock, valued at $836,305.14. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 53.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CALC. Hudson Bay Capital Management LP acquired a new stake in CalciMedica during the 3rd quarter worth about $432,000. Meritage Portfolio Management grew its holdings in CalciMedica by 360.0% during the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after acquiring an additional 36,000 shares during the period. Finally, BML Capital Management LLC raised its position in CalciMedica by 63.8% during the fourth quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock valued at $416,000 after acquiring an additional 56,643 shares in the last quarter.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.